Kolon Life Science Past Earnings Performance
Past criteria checks 0/6
Kolon Life Science has been growing earnings at an average annual rate of 62.6%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
62.6%
Earnings growth rate
62.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 6.5% |
| Return on equity | -24.4% |
| Net Margin | -27.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02
We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns
Jan 18Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26
Revenue & Expenses BreakdownBeta
How Kolon Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 124,639 | -33,599 | 20,227 | 14,892 |
| 30 Sep 23 | 161,171 | -21,657 | 22,211 | 13,555 |
| 30 Jun 23 | 172,045 | -13,752 | 22,159 | 12,927 |
| 31 Mar 23 | 194,956 | -2,742 | 22,114 | 14,220 |
| 31 Dec 22 | 161,584 | 4,016 | 19,581 | 13,583 |
| 30 Sep 22 | 166,885 | -4,828 | 17,196 | 14,707 |
| 30 Jun 22 | 167,707 | -4,940 | 17,136 | 14,653 |
| 31 Mar 22 | 155,075 | -3,693 | 17,170 | 13,550 |
| 31 Dec 21 | 165,485 | -1,375 | 17,320 | 14,327 |
| 30 Sep 21 | 135,045 | -31,627 | 20,062 | 13,804 |
| 30 Jun 21 | 134,850 | -29,154 | 21,739 | 14,032 |
| 31 Mar 21 | 131,508 | -40,485 | 25,030 | 13,634 |
| 31 Dec 20 | 129,413 | -43,195 | 27,888 | 13,154 |
| 31 Dec 19 | 148,541 | -92,323 | 30,452 | 18,490 |
| 30 Sep 13 | 139,921 | 18,056 | 15,176 | 11,672 |
| 30 Jun 13 | 141,626 | 20,837 | 14,804 | 11,219 |
Quality Earnings: A102940 is currently unprofitable.
Growing Profit Margin: A102940 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A102940 is unprofitable, but has reduced losses over the past 5 years at a rate of 62.6% per year.
Accelerating Growth: Unable to compare A102940's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A102940 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.1%).
Return on Equity
High ROE: A102940 has a negative Return on Equity (-24.41%), as it is currently unprofitable.